Tradestie Institutional Equity Comparison Engine

DNA vs MEDI โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

MEDI Overall Edge

MEDI Captures Institutional Edge (2โ€“1 Pillars ยท 2โ€“6 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Harbor Health Care ETF (MEDI) driven by superior Momentum & Technical, Options & Structure while DNA counters with relative strength in Growth & Margin. Fundamentally, DNA trades at N/M Forward P/E with -202.5% operating margin (-5.7% YoY revenue) versus MEDI at N/M Forward P/E and N/A operating margin (N/A YoY). In options structure, DNA sits in BREAKDOWN (34th %ile IV; Dealer Gamma Walls on Pro) against MEDI sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
DNA N/M vs MEDI N/M Fwd P/E
Growth & Margin Winner DNA
Op Margin -202.5% vs N/A ยท YoY -5.7% vs N/A
Momentum & Technical Winner MEDI
1Y +6.2% vs +14.7% ยท 52W Pos 24% vs 90%
Options & Structure Winner MEDI
BREAKDOWN (34th %ile IV) vs UNCLASSIFIED (N/A IV)
DNA NYSE
Ginkgo Bioworks Holdings, Inc.
Biological Products, (No Disgnostic Substances)
$8.50
-11.55% 1D
Market Cap $623.0M
1M Return -17.23%
1Y Return +6.25%
Forward P/E N/M
Unified AI Score
57.4 / 100 HOLD
Tech 40.0 Fund 52.0 Flow 68.0 Mom 50.0
MEDI NYSE Arca
Harbor Health Care ETF
Institutional Equity
$35.59
-2.05% 1D
Market Cap N/A
1M Return +9.92%
1Y Return +14.68%
Forward P/E N/M
Unified AI Score
42.1 / 100 HOLD
Tech 25.0 Fund 39.0 Flow 50.0 Mom 22.2

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: DNA +6.25% MEDI +14.68% Spread: +8.43 pp (MEDI Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
DNA TTM Op. Margin: -202.5% MEDI TTM Op. Margin: N/A
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on DNA vs MEDI. Trailing 12-month operating profitability (DNA -202.5% vs MEDI N/A) and valuation multiples (DNA N/M vs MEDI N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: DNA (6) vs MEDI (2)
Institutional Metric DNA MEDI Criterion Row Winner
Market Capitalization Scale $623.0M N/A Larger Scale DNA
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -5.7% N/A Higher Growth DNA
Operating Margin (TTM) Profitability -202.5% N/A Higher Margin DNA
Net Profit Margin Profitability -192.0% N/A Higher Margin DNA
Return on Equity (ROE) Capital Efficiency -58.2% N/A Higher ROE DNA
52-Week Range Position Momentum 24% ($5โ€“$18) 90% ($28โ€“$37) Stronger Trend MEDI
Beta / 30D Volatility Risk Regime 3.14ฮฒ ยท 152% Vol 0.59ฮฒ ยท 22% Vol Lower Realized Risk MEDI
Unified Institutional Score Composite Signal 57.4 / 100 (HOLD) 42.1 / 100 (HOLD) Higher Composite DNA

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full DNA vs MEDI Buy Guide
DNA BREAKDOWN
30d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 34th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live DNA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
MEDI UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live MEDI Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither DNA nor MEDI registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.